Beauty Health (SKIN) AI Stock Analysis

• Market Cap: $294.23M
• Dividend Yield: N/A
• Average Volume (3M): 1.15M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.68
• Revenue Growth: -15.33%
• EPS Growth: 75.52%
• Country: US
• Employees: 769
• Sector: Consumer Defensive
• Sector Strength: 64
• Industry: Household & Personal Products
• EPS (TTM): 0.16
• Shares Outstanding: 126,825,390
• 10 Day Avg. Volume: 2,125,113
• 30 Day Avg. Volume: 1,149,946
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.47
• Enterprise Value/Revenue: 1.34
• Enterprise Value/Gross Profit: 2.37
• Enterprise Value/Ebitda: -55.33
• 1Y Price Target: $1.88
• Price Target Upside: -13.36% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 5

• Rating: 53 Neutral
• Price Target: $2.00 ▼(-7.83% Downside)

The overall stock score is primarily influenced by significant financial challenges, including declining revenues and high leverage. Despite improvements in cash flow and positive earnings call highlights, such as exceeding revenue and EBITDA guidance, the company's valuation remains unattractive due to ongoing losses. Technical analysis provides a mixed outlook, with positive short-term trends but potential bearish momentum.

Positive Factors

Cash Position

The company ended the quarter with a solid $212 million in cash, which provides financial stability.

Earnings

Beauty Health's first-quarter sales exceeded expectations despite macroeconomic pressures.

Financial Performance

The company's consumables now represent 71% of net sales and carry stronger margins compared to delivery systems, supporting an EBITDA margin outperformance.

Negative Factors

Device Sales

There are continued declines in device sales driven by a worsening macroeconomic environment and higher rates of provider churn.

Leverage

Leverage remains elevated given the recent decline in EBITDA, which could recover as management's initiatives take hold but acknowledge it could take some time.

Macroeconomic Conditions

New machine placements remain pressured due to the higher interest rate environment and uncertain macro conditions.

Beauty Health Business Overview & Revenue Model

Company Description

Beauty Health (SKIN) is a company that operates in the beauty and wellness sectors, primarily focusing on skincare products and treatments. The company is known for its innovative approaches to skin health, offering a range of products and services designed to enhance and maintain skin vitality.

How the Company Makes Money

Beauty Health makes money through the sale of its skincare products and services, which include a variety of treatments and therapies aimed at improving skin health. The company generates revenue by selling its products directly to consumers through retail and online channels, as well as through partnerships with spas, clinics, and beauty professionals who offer its treatments. Additionally, Beauty Health may engage in licensing agreements or collaborations with other brands to expand its market presence and drive sales.

Beauty Health Financial Statement Overview

Summary

Beauty Health faces significant financial challenges with declining revenues and profitability issues. While cash flow has improved, high leverage and negative profit margins highlight risks. The company needs to address operational inefficiencies and manage debt levels to ensure long-term financial stability.

Income Statement

The company exhibits declining revenue, with a growth rate of -3.53% from 2024 to TTM. Profit margins are negative due to significant net losses, demonstrated by a TTM net profit margin of -11.94%. The gross profit margin stands at 56.60%, indicating a decent cost management relative to revenue. However, negative EBIT and EBITDA margins suggest operational inefficiencies.

Balance Sheet

The balance sheet reveals high leverage, with a debt-to-equity ratio of 12.32, posing a substantial risk. The equity ratio is low at 6.83%, indicating limited equity cushion. Return on equity is negative due to net losses. The company's reliance on debt over equity increases financial risk.

Cash Flow

Cash flow analysis shows improvement, with a 219.42% growth in free cash flow from 2024 to TTM. The operating cash flow to net income ratio indicates better cash generation than reported net income. However, the free cash flow to net income ratio is still below optimal levels, suggesting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	322.47M	334.29M	397.99M	365.88M	260.09M	119.09M
Gross Profit	182.51M	182.30M	155.11M	248.78M	178.54M	67.20M
EBITDA	-7.82M	10.34M	-53.56M	80.75M	-22.00M	-2.81M
Net Income	-38.52M	-29.10M	-100.12M	44.22M	-375.11M	-29.18M
Balance Sheet
Total Assets	673.82M	685.68M	929.11M	1.01B	1.22B	222.84M
Cash, Cash Equivalents and Short-Term Investments	373.03M	370.06M	523.02M	568.20M	901.89M	9.49M
Total Debt	567.69M	568.16M	752.29M	751.79M	746.41M	216.54M
Total Liabilities	627.76M	633.88M	869.72M	837.43M	916.51M	252.79M
Stockholders Equity	46.06M	51.80M	59.39M	171.48M	302.30M	-29.96M
Cash Flow
Free Cash Flow	29.85M	9.34M	8.70M	-123.99M	-43.98M	-16.25M
Operating Cash Flow	35.98M	16.13M	21.75M	-106.60M	-28.36M	-12.44M
Investing Cash Flow	-6.14M	-6.79M	-31.51M	-18.87M	-37.73M	-3.82M
Financing Cash Flow	-99.97M	-158.34M	-37.45M	-205.24M	959.03M	18.27M

Beauty Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SKIN, the sentiment is Positive. The current price of 2.17 is above the 20-day moving average (MA) of 1.81, above the 50-day MA of 1.81, and above the 200-day MA of 1.56, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 60.54 is Neutral, neither overbought nor oversold. The STOCH value of 80.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SKIN.

Beauty Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NUS	74 Outperform	$551.90M	5.56	13.68%	2.10%	-11.79%	―
EWCZ	68 Neutral	$258.89M	23.39	10.89%	―	-5.04%	-22.16%
Sector *	63 Neutral	$20.98B	14.59	-8.07%	3.13%	2.83%	-9.85%
COTY	61 Neutral	$4.35B	40.12	-10.58%	―	-1.68%	-302.11%
EPC	57 Neutral	$1.05B	16.63	4.12%	2.58%	-2.92%	-43.06%
SKIN	53 Neutral	$294.23M	―	-26.54%	―	-15.33%	75.52%
HELE	47 Neutral	$541.06M	5.74	-23.99%	―	-4.39%	-326.42%

Beauty Health Corporate Events

Beauty Health Amends Governance Documents and Leadership

On July 31, 2025, The Beauty Health Company filed a Certificate of Correction to amend an error in its corporate governance documents, allowing directors to be removed with or without cause by a majority vote. Additionally, the Board appointed Stephen Fanning as Chairman of the Nominating and Corporate Governance Committee, reflecting a strategic move in its leadership structure.

The most recent analyst rating on (SKIN) stock is a Hold with a $1.20 price target. To see the full list of analyst forecasts on Beauty Health stock, see the SKIN Stock Forecast page.

Beauty Health Holds Virtual Annual Stockholders Meeting

On June 12, 2025, The Beauty Health Company held its annual stockholders meeting virtually, where 78.40% of the shares were represented, establishing a quorum. During the meeting, seven directors were elected for a one-year term, Deloitte & Touche LLP was ratified as the independent auditor, and the compensation for named executive officers was approved on a non-binding basis.

The most recent analyst rating on (SKIN) stock is a Hold with a $1.20 price target. To see the full list of analyst forecasts on Beauty Health stock, see the SKIN Stock Forecast page.

Beauty Health Issues $250M Convertible Notes

On May 27, 2025, The Beauty Health Company issued $250 million in 7.95% Convertible Senior Secured Notes due 2028, which are senior secured obligations guaranteed by certain subsidiaries and secured by substantially all assets of the company. This financial move is significant for the company’s operations as it provides liquidity and flexibility, allowing noteholders the option to convert notes into common stock, with provisions for adjustments in conversion rates upon certain corporate events, potentially impacting stakeholders by altering the company’s capital structure and market positioning.

The most recent analyst rating on (SKIN) stock is a Hold with a $1.20 price target. To see the full list of analyst forecasts on Beauty Health stock, see the SKIN Stock Forecast page.

Beauty Health Refinances Debt to Strengthen Position

On May 21, 2025, The Beauty Health Company announced it had entered into exchange agreements to refinance its debt, exchanging $413.2 million of existing convertible notes for $250 million of new senior secured notes due 2028 and $143.4 million in cash. This move aims to strengthen the company’s financial position and extend debt maturity, allowing for greater investment in growth strategies, including product development and brand initiatives.

The most recent analyst rating on (SKIN) stock is a Hold with a $1.20 price target. To see the full list of analyst forecasts on Beauty Health stock, see the SKIN Stock Forecast page.